FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced interim data from the ongoing Phase 2 ELECTRON study examining a 12-week course of therapy with the investigational nucleotide sofosbuvir, the NS5A inhibitor GS-5885 and ribavirin in patients with genotype 1 chronic hepatitis C virus or HCV infection. According to the company, among treatment-naïve patients receiving this combination, 100 percent remained HCV RNA undetectable four weeks after completing therapy.
'These results indicate that adding GS-5885 to sofosbuvir-based regimens may enhance SVR rates, potentially offering HCV genotype 1 infected patients a convenient 12-week course of oral therapy,' said Professor Edward Gane, MD, Deputy Director and Hepatologist, New Zealand Liver Transplant Unit, Auckland City Hospital in New Zealand, and principal investigator of the ELECTRON study. 'Along with other data from the ELECTRON study, these results add to the growing body of evidence supporting the potential for effective sofosbuvir-based all-oral regimens.'
Recently, Gilead initiated the first Phase 3 study assessing a fixed-dose combination of sofosbuvir and GS-5885 in treatment-naïve genotype 1 patients. This four-arm trial is evaluating the fixed-dose combination with and without ribavirin for 12-and 24-week durations in 800 patients, 20 percent of whom have evidence of cirrhosis.
Copyright RTT News/dpa-AFX
© 2012 AFX News
